CA2961587A1 - Compositions and methods of use for treating metabolic disorders - Google Patents

Compositions and methods of use for treating metabolic disorders Download PDF

Info

Publication number
CA2961587A1
CA2961587A1 CA2961587A CA2961587A CA2961587A1 CA 2961587 A1 CA2961587 A1 CA 2961587A1 CA 2961587 A CA2961587 A CA 2961587A CA 2961587 A CA2961587 A CA 2961587A CA 2961587 A1 CA2961587 A1 CA 2961587A1
Authority
CA
Canada
Prior art keywords
polypeptide
complex
sequence
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2961587A
Other languages
English (en)
French (fr)
Other versions
CA2961587C (en
Inventor
Wenyan Shen
Darrin Anthony Lindhout
Raj Haldankar
Hugo Matern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Publication of CA2961587A1 publication Critical patent/CA2961587A1/en
Application granted granted Critical
Publication of CA2961587C publication Critical patent/CA2961587C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2961587A 2014-10-31 2015-10-29 Compositions and methods of use for treating metabolic disorders Active CA2961587C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462073737P 2014-10-31 2014-10-31
US62/073,737 2014-10-31
US201562244604P 2015-10-21 2015-10-21
US62/244,604 2015-10-21
PCT/US2015/058111 WO2016069921A1 (en) 2014-10-31 2015-10-29 Compositions and methods of use for treating metabolic disorders

Publications (2)

Publication Number Publication Date
CA2961587A1 true CA2961587A1 (en) 2016-05-06
CA2961587C CA2961587C (en) 2025-09-09

Family

ID=

Also Published As

Publication number Publication date
EP3212226A4 (en) 2018-04-11
EA036985B1 (ru) 2021-01-25
DK3212226T3 (da) 2020-06-15
CO2017003487A2 (es) 2017-09-11
US20160120999A1 (en) 2016-05-05
TW201625698A (zh) 2016-07-16
US11530260B2 (en) 2022-12-20
US20200140536A1 (en) 2020-05-07
AP2017009828A0 (en) 2017-03-31
KR102672706B1 (ko) 2024-06-07
ECSP17021754A (es) 2017-05-31
US12173060B2 (en) 2024-12-24
CN106687128A (zh) 2017-05-17
TWI703161B (zh) 2020-09-01
IL251066A0 (en) 2017-04-30
EA201790405A1 (ru) 2017-09-29
AU2015339130C1 (en) 2021-03-18
US9920118B2 (en) 2018-03-20
SG11201702580PA (en) 2017-05-30
WO2016069921A1 (en) 2016-05-06
CN115043945A (zh) 2022-09-13
NZ730054A (en) 2023-11-24
US20180237514A1 (en) 2018-08-23
EP3212226A1 (en) 2017-09-06
JP2017538395A (ja) 2017-12-28
GT201700072A (es) 2018-11-27
PE20171058A1 (es) 2017-07-21
EP3212226B1 (en) 2020-03-18
IL251066B (en) 2021-06-30
BR112017005986A2 (pt) 2017-12-19
CL2017000864A1 (es) 2018-05-11
MY186702A (en) 2021-08-11
DOP2017000097A (es) 2017-05-15
MX2017005237A (es) 2017-06-30
TN2017000113A1 (en) 2018-07-04
US10562965B2 (en) 2020-02-18
EP3701969A1 (en) 2020-09-02
ES2799503T3 (es) 2020-12-18
AU2015339130A1 (en) 2017-04-06
PL3212226T3 (pl) 2020-11-02
KR20170074852A (ko) 2017-06-30
PH12017500680A1 (en) 2017-10-09
PT3212226T (pt) 2020-06-22
JP6722175B2 (ja) 2020-07-15
NI201700042A (es) 2017-05-04
UA121973C2 (uk) 2020-08-25
MD20170035A2 (ro) 2017-09-30
US20230312696A1 (en) 2023-10-05
CN106687128B (zh) 2022-05-10
MX357994B (es) 2018-08-01
SV2017005420A (es) 2017-10-17
AU2015339130B2 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
US12173060B2 (en) Compositions and methods of use for treating metabolic disorders
US11358995B2 (en) Compositions and methods of use for treating metabolic disorders
CA2961587C (en) Compositions and methods of use for treating metabolic disorders
HK40035218A (en) Compositions and methods of use for treating metabolic disorders
HK1242595B (en) Compositions and methods of use for treating metabolic disorders
HK1242595A1 (en) Compositions and methods of use for treating metabolic disorders
NZ728101B2 (en) Compositions and methods of use for treating metabolic disorders
HK1237790B (en) Compositions and methods of use for treating metabolic disorders
BR112017005986B1 (pt) Complexo que compreende um primeiro heterodímero e um segundo heterodímero, composição farmacêutica e uso do complexo

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029